Felix Hoffmann: Life and Career (1868–1946)

Felix Hoffmann (1868–1946) is one of the few industrial chemists whose name ordinary readers still meet. In 1897, working in a company laboratory in the German textile town of Elberfeld, he made acetylsalicylic acid in a pure and stable form — the substance that went on sale in 1899 as aspirin and became one of the most widely used medicines of the twentieth century. Yet the man himself left only a thin trail. He spent most of his working life in management rather than at the bench, and he died in Switzerland in 1946. Almost everything known about his life comes from a short entry in the German national biography, the records of his employer and patents, and the historians who later went back to the archives.

This page tells the story of the man: the Ludwigsburg family he came from, his training as a pharmacist in three cities, his chemistry doctorate in Munich, the professor whose word got him his job, the laboratory at Elberfeld, the year 1897 told in brief, his move to the commercial side of the pharmaceutical business, his retirement among the art of Italy and Switzerland, and how his reputation as “the inventor of aspirin” was first built and later questioned. The chemistry of the discovery and the dispute over credit are told in full in The 1897 Synthesis of Aspirin and the Eichengrün Question; the willow and meadowsweet story behind the molecule in Willow Bark, Meadowsweet and the Natural Salicylates Behind Aspirin; and what aspirin became afterwards in How Aspirin Works.

Table of Contents

  1. 1. A Manufacturer’s Son from Ludwigsburg
  2. 2. Apprenticed in Pharmacy: Geneva, Hamburg and Neuveville
  3. 3. Chemistry in Munich and a Doctorate Under Eugen Bamberger
  4. 4. Recommended by Adolf von Baeyer
  5. 5. The Pharmaceutical Laboratory at Elberfeld, 1894
  6. 6. The Year 1897 in Brief
  7. 7. From the Laboratory Bench to the Commercial Side
  8. 8. Retirement, Art and Switzerland
  9. 9. How Hoffmann Came to Be Remembered
  10. 10. Timeline of Felix Hoffmann’s Life
  11. Key Research Papers
  12. Connections
  13. Featured Videos

1. A Manufacturer’s Son from Ludwigsburg

Felix Hoffmann was born on 21 January 1868 in Ludwigsburg, a garrison and former royal residence town a few kilometres north of Stuttgart in the Kingdom of Württemberg. Germany had not yet been unified; that would come three years later, in 1871, and Hoffmann grew up in the decades when the new empire was turning itself into the leading chemical nation of the world.

According to the Neue Deutsche Biographie (NDB), the standard German national biography, his father was Reinhold Hoffmann, a manufacturer in Ludwigsburg, and his mother was Emilie, a daughter of the instrument maker Ferdinand Käferle. The family was therefore part of the small-town industrial middle class: people who made things, kept workshops, and expected their sons to learn a trade or a profession.

Hoffmann attended the Latin school (Lateinschule) in Ludwigsburg. In the German states of the time a Latin school gave a classical secondary education — Latin, mathematics and the sciences — that led either to a university or to one of the learned trades. Pharmacy was one of those trades, and it was the one Hoffmann chose.

A popular later story says that Hoffmann made aspirin to relieve his father’s rheumatism. The historian Walter Sneader traced that story to a footnote first printed in 1934, in a history of chemical engineering by Albrecht Schmidt, nearly forty years after the event, and argued that it is not a reliable source. It is told here as a later account, not as established fact; the details are on the 1897 synthesis page.

Back to Table of Contents

2. Apprenticed in Pharmacy: Geneva, Hamburg and Neuveville

In the nineteenth century a German pharmacist was trained first in the shop and only afterwards at a university. A young man served an apprenticeship and then worked as an assistant in a working pharmacy, learning to identify and test crude drugs — barks, roots, resins, leaves and mineral salts — and to compound them into powders, tinctures, pills and ointments by hand. It was practical, sensory work, close to the old herbal tradition from which most medicines of the day still came.

The NDB records that Hoffmann served his pharmacy apprenticeships between 1886 and 1889 in three places: Geneva, in French-speaking Switzerland; Hamburg, the great North German port; and Neuveville (La Neuveville), a small town on Lake Biel in the French-speaking part of the Swiss canton of Bern. The choice of two Swiss towns meant that the young chemist learned his trade partly in French, and it began a lifelong connection with Switzerland that would end with his death there nearly sixty years later.

Pharmacies of the 1880s still sold the plant medicines whose chemistry would later shape Hoffmann’s career. Willow bark and meadowsweet, the plants that gave medicine salicin and salicylic acid, were part of the old materia medica, and salicylic acid and its sodium salt were by then standard remedies for fever and rheumatic pain. Whether Hoffmann handled them as an apprentice is not recorded, but they were the ordinary stock of the trade he learned. Their story is told in Willow Bark, Meadowsweet and the Natural Salicylates Behind Aspirin.

Back to Table of Contents

3. Chemistry in Munich and a Doctorate Under Eugen Bamberger

After his years in the pharmacy, Hoffmann went to the University of Munich to study pharmacy and chemistry. He passed the pharmaceutical state examination in 1891, the qualification that allowed a pharmacist to practise in Germany. Instead of returning to a shop, he stayed on to study chemistry at a deeper level.

Munich was then one of the best places in the world to learn organic chemistry, the chemistry of carbon compounds. Its chemistry institute was led by Adolf von Baeyer, the chemist who had worked out the structure of indigo and would receive the Nobel Prize in Chemistry in 1905. Around him worked a group of younger researchers who trained a whole generation of German industrial chemists.

One of them was Eugen Bamberger, and it was under Bamberger that Hoffmann took his doctorate in 1893. According to the NDB, his dissertation dealt with derivatives of anthracene and quinoline — specifically dihydroanthracene and decahydroquinoline. Both parent compounds come from coal tar, the black by-product of gas works and coke ovens that was the raw material of the new chemical industry. Anthracene was the starting point for the synthetic red dye alizarin; quinoline is a ring structure found in quinine, the antimalarial alkaloid of cinchona bark, and in many later synthetic drugs. Adding hydrogen atoms to such rings, as Hoffmann’s compounds required, was exactly the kind of careful structural chemistry the dye and drug laboratories needed.

His training thus combined two worlds: the pharmacist’s practical knowledge of medicines and the research chemist’s skill in changing a molecule one group at a time. That combination is what made him useful to an industrial pharmaceutical laboratory.

Back to Table of Contents

4. Recommended by Adolf von Baeyer

German chemical firms of the 1890s recruited their research chemists largely through professors. A leading professor who knew a student’s work could place him in industry with a word, and the companies relied on those recommendations because the universities were where the skills were taught.

The NDB and the Science History Institute both record that Hoffmann joined the Farbenfabriken Bayer at Elberfeld in 1894 on the recommendation of Adolf von Baeyer, his professor at Munich. (The firm is named here only as a plain historical fact; the similarity between “Baeyer” the professor and “Bayer” the company is a coincidence of spelling, and the two were not related.)

The recommendation placed Hoffmann at the meeting point of two traditions. Von Baeyer stood for academic organic chemistry; the Elberfeld company had begun as a dye maker and was now moving into medicines. Across the German dye industry in the 1880s and 1890s, chemists were finding that the same coal-tar chemistry that produced colours could also produce fever remedies, pain relievers and sleeping drugs, and several firms were building pharmaceutical research groups to do it.

Back to Table of Contents

5. The Pharmaceutical Laboratory at Elberfeld, 1894

Elberfeld, today part of the city of Wuppertal in the Rhineland, was a textile town on the river Wupper, and its dye works had grown up to serve the cloth trade. When Hoffmann arrived in 1894 he joined the company’s pharmaceutical laboratory, a small research group whose task was to find new medicines that could be made from the firm’s chemical know-how and sold under its name.

The work was organised in a way that later became standard in drug companies. Chemists such as Hoffmann made new compounds or purer forms of old ones; a separate pharmacological laboratory then tested them in animals and judged whether they were worth trying in patients. At Elberfeld in the late 1890s the pharmacological laboratory was headed by Heinrich Dreser, who would publish the first pharmacology paper on aspirin in 1899. Arthur Eichengrün, another chemist in the pharmaceutical group, later became central to the question of who deserves the credit for aspirin.

A great deal of the laboratory’s effort went into improving existing medicines: making a known drug easier to take, less irritating or more stable on the shelf. Salicylic acid was an obvious candidate. It worked against fever and rheumatic pain, but in the doses then used it and its sodium salt irritated the stomach, tasted unpleasant and caused other side effects that many patients found hard to tolerate. Finding a gentler salicylate was a practical industrial problem, and it was this problem that Hoffmann’s best-known work addressed.

Back to Table of Contents

6. The Year 1897 in Brief

On 10 August 1897 Hoffmann wrote a laboratory report describing acetylsalicylic acid in a pure form suitable for medical use. Acetylsalicylic acid is salicylic acid with an acetyl group (a small two-carbon fragment from acetic acid, the acid of vinegar) attached to its hydroxyl group. The compound was not new: the French chemist Charles Gerhardt had made a form of it in 1853 during his studies of acid anhydrides, and other chemists had described related products since. What Hoffmann achieved, in the words of the NDB, was the substance “in pure, stable form”.

Dreser’s laboratory tested it, and Dreser’s paper on its pharmacology appeared in 1899. The same year the company put the medicine on sale under the name Aspirin: “A” for acetyl, and “spir” recalling Spiraea, the old botanical name of meadowsweet, from which salicylic acid had once been obtained. The NDB states that the new compound proved superior to sodium salicylate because it had fewer side effects. In the United States, Hoffmann was named as the inventor on Patent 644,077, “Acetyl Salicylic Acid”, applied for on 1 August 1898 and granted on 27 February 1900; a German patent was refused because the compound had been described before.

In the same period, working at Dreser’s direction, Hoffmann also acetylated morphine, the main alkaloid of opium, producing diacetylmorphine, which the company marketed as heroin. That substance had already been made in 1874 by an English chemist. It is mentioned here as history only.

Whether the idea of making acetylsalicylic acid was Hoffmann’s own, or whether he was carrying out the instruction of his colleague Arthur Eichengrün, is the subject of a long dispute that historians still discuss. The full account — Gerhardt’s compound, the August report, Dreser’s tests, the naming, the patents and the Eichengrün question — is on The 1897 Synthesis of Aspirin and the Eichengrün Question.

Back to Table of Contents

7. From the Laboratory Bench to the Commercial Side

For most of his career Hoffmann was not a research chemist at all. The NDB records that after aspirin’s introduction he moved to the commercial side of the pharmaceutical business and directed its commercial-pharmaceutical (marketing) department. In other words, the chemist who had made the compound became one of the people responsible for presenting the company’s medicines to pharmacists and physicians.

The move made sense for a man with his background. A trained pharmacist with a chemistry doctorate understood both how medicines were made and how they were dispensed and prescribed, and he spoke the language of the pharmacists and doctors who were the industry’s customers. A medicine of that era was sold largely through the medical and pharmaceutical professions, and someone who had worked both in a pharmacy and in the laboratory was well placed to explain it to them.

Little else is recorded about these years. Hoffmann did not build a scientific career of papers and prizes, and the record does not credit him with any later discovery on the scale of 1897. He remained with the company for more than three decades, through the First World War, after which, as the historians note, the aspirin trademark was lost in several countries and the word passed into common use. The story of what aspirin became in the twentieth century is told on How Aspirin Works.

Back to Table of Contents

8. Retirement, Art and Switzerland

Hoffmann was pensioned in 1928, at the age of sixty. According to the NDB he then devoted himself to art-historical interests, which he pursued in Italy and Switzerland. The pharmacist-chemist who had spent his career among laboratory benches and sales departments spent his last years among churches, paintings and collections — an interest that seems to have been personal and private, since no writings of his on art are recorded.

Switzerland, where he had served two of his apprenticeships as a young man, was where his life ended. Felix Hoffmann died in Lausanne, on Lake Geneva, on 8 February 1946, at the age of seventy-eight.

The sources used for this page record no public honours or scientific prizes for him. His name survived chiefly through the documents of 1897–1900 — the laboratory report and the patent — and through the histories of aspirin written later, which are the subject of the next section.

Back to Table of Contents

9. How Hoffmann Came to Be Remembered

The record that built the reputation

Several kinds of document put Hoffmann’s name at the centre of the aspirin story. His 10 August 1897 laboratory report described the pure compound. The United States patent of 1900 named him as the inventor. The 1934 footnote in Albrecht Schmidt’s history of chemical engineering gave the story a personal motive, the father with rheumatism, which proved memorable and was retold for decades. According to the commentary by John Wood, the company’s own histories continued to credit Hoffmann. By 1972, when the NDB published its entry on him, he was described as the chemist who had made acetylsalicylic acid in pure, stable form. Popular histories, school textbooks and the centenary of 1997 — marked by retrospectives such as “One hundred years of aspirin” in the Lancet and in Medical History — spread the name worldwide.

The account that questioned it

The challenge came from Arthur Eichengrün, the chemist who had worked alongside him at Elberfeld. Eichengrün was Jewish. Under Nazi persecution he was silent for years after 1934, and in 1944 he was held at the Theresienstadt camp, from where he wrote about the matter. In 1949 he published his account, stating that he had instructed Hoffmann to make acetylsalicylic acid and that his own clinical trials, carried out without Dreser’s knowledge, had led to the medicine being marketed despite Dreser’s opposition. He also pointed out that an exhibit at the Deutsches Museum in Munich credited aspirin only to Dreser and Hoffmann.

In 2000 the pharmacologist and historian Walter Sneader re-examined the documents in the BMJ. He noted, among other points, that the last sentence of Hoffmann’s 1897 report says the substance was being examined for its usefulness, which fits with testing already under way, and he argued that Eichengrün’s account deserves to be taken seriously. Wood (2015) summarised Eichengrün’s claim that his part had been removed from the record during the Nazi period and noted that Sneader supports that view. The historian Elisabeth Vaupel of the Deutsches Museum published a full biography of Eichengrün in 2005. The Science History Institute now writes that some evidence indicates that Eichengrün played a significant role and that he may have been left out because he was Jewish.

Where that leaves Hoffmann

The historians’ accounts summarised here do not dispute that Hoffmann carried out the synthesis described in the 1897 report. The open question is how much of the idea and the push to market it came from him, and how much from Eichengrün. On the present evidence, the credit for aspirin is best described as disputed: Hoffmann made the pure compound, and the historians who have reopened the files argue that the story of the discovery was larger than one man. Both chemists, and Dreser, have long since died; the dispute is reported here as documented history, attributed to the historians who have studied it.

Back to Table of Contents

10. Timeline of Felix Hoffmann’s Life

Back to Table of Contents

Key Research Papers

  1. Sneader W. The discovery of aspirin: a reappraisal. BMJ. 2000;321(7276):1591-4. PubMed PMID: 11124191
  2. Vaupel E. Arthur Eichengrün--tribute to a forgotten chemist, entrepreneur, and German Jew. Angew Chem Int Ed Engl. 2005;44(22):3344-55. PubMed PMID: 15798983
  3. Wood JN. From plant extract to molecular panacea: a commentary on Stone (1763) ‘An account of the success of the bark of the willow in the cure of the agues’. Philos Trans R Soc Lond B Biol Sci. 2015;370(1666):20140317. PubMed PMID: 25750237
  4. Hedner T, Everts B. The early clinical history of salicylates in rheumatology and pain. Clin Rheumatol. 1998;17(1):17-25. PubMed PMID: 9586674
  5. Gerhardt Ch. Untersuchungen über die wasserfreien organischen Säuren. Justus Liebigs Annalen der Chemie. 1853;87(1):57-84. DOI: 10.1002/jlac.18530870107
  6. Dreser H. Pharmakologisches über Aspirin (Acetylsalicylsäure). Pflüger, Archiv für die Gesammte Physiologie des Menschen und der Thiere. 1899;76(5-6):306-318. DOI: 10.1007/bf01662127
  7. Jack DB. One hundred years of aspirin. Lancet. 1997;350(9075):437-9. PubMed PMID: 9259670
  8. Rinsema TJ. One hundred years of aspirin. Med Hist. 1999;43(4):502-7. PubMed PMID: 10885147
  9. Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots - A concise summary. Vascul Pharmacol. 2019;113:1-8. PubMed PMID: 30391545
  10. Desborough MJR, Keeling DM. The aspirin story - from willow to wonder drug. Br J Haematol. 2017;177(5):674-683. PubMed PMID: 28106908
  11. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110(5-6):255-8. PubMed PMID: 14592543

PubMed Topic Searches

  1. https://pubmed.ncbi.nlm.nih.gov/?term=aspirin+history
  2. https://pubmed.ncbi.nlm.nih.gov/?term=Hoffmann+aspirin+1897
  3. https://pubmed.ncbi.nlm.nih.gov/?term=Eichengrun+aspirin
  4. https://pubmed.ncbi.nlm.nih.gov/?term=acetylsalicylic+acid+discovery+history

Further Reading

Back to Table of Contents

Connections

Back to Table of Contents